Status:
UNKNOWN
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
Lead Sponsor:
Osaka University
Collaborating Sponsors:
Bayer
Conditions:
Renal Insufficiency, Chronic
Hyperphosphatemia
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the effect of lanthanum carbonate and calcium carbonate on the progression of coronary calcification and vascular endothelial dysfunction.
Eligibility Criteria
Inclusion
- Hyperphosphatemia (For patients without calcium carbonate, ≥4.5 mg/dL) (For patients with calcium carbonate, ≥4.0 mg/dL)
- With written informed consent
Exclusion
- History of cardiac surgery
- With coronary artery stent
- Polycystic kidney disease
- Hypothyroidism
- On treatment with lanthanum carbonate
- History of admission within 3 months
- History of ileus
- Severe liver dysfunction
- Severe gastrointestinal dysfunction
- Allergy to lanthanum carbonate or calcium carbonate
- Pregnant or breastfeeding women
- Judged as ineligible by the investigator
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02237534
Start Date
September 1 2014
End Date
September 1 2023
Last Update
February 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka University Hospital
Suita, Osaka, Japan, 565-0871